Company: RPTX
Filing Date: 2025-11-17
Form Type: 8-K
Source: 0001193125-25-284035
Chunk: 5

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: 8-K
Item: Item 1.01
Chunk 5
---
 and projections regarding, among other things, the expected date of closing of the Transaction and the potential benefits thereof, its business and industry, management’s beliefs and certain assumptions made by the Company, all of which are subject to change. Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, and which may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, including the consummation of the Transaction and the anticipated benefits thereof. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this Current Report on Form 8-K. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this Current Report on Form 8-Kare identified in the section titled “ Risk Factors” in the Company’s Annual Report on Form10-Kfor the year ended December 31, 2024 filed with the Securities and Exchange Commission (“ SEC”) and the Québec Autorité des Marchés Financiers (“ AMF”) on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company’s Quarterly Report on Form10-Qfor the quarter ended September 30, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.